NCT04340908

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Hongchang Guo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with diabetes have poorer cardiac surgery outcomes compared with non-diabetics. Proper blood glucose management is critical to reduce the morbidity and mortality for diabetic patients after cardiac surgery. SGLT2 inhibitors including dapagliflozin as a new diabetes drug can reduce heart failure hospitalization rates and overall cardiovascular mortality in patients with cardiovascular disease. This study is to assess the impact of one year of treatment of SGLT2 inhibitors on cardiac function, postoperative complications and long-term cardiovascular mortality in diabetic patients undergoing cardiac surgery. The investigators use echocardiography to evaluated cardiac function in diabetic patients during perioperative cardiac surgery.

Conditions

• Diabetes Mellitus, Type 2
• Cardiac Surgery

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10 MG	10 mg tablet, oral, once daily, 1-year treatment, postoperation
DRUG	Placebos	matching placebo tablet, oral, once daily, 1-year treatment, postoperation

Timeline

• Start date: 2021-01-01
• Primary completion: 2022-06-01
• Completion: 2023-06-01
• First posted: 2020-04-10
• Last updated: 2021-10-07

Locations

1 site across 1 country: China